Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Endocrinology ; 152(12): 4691-705, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21933863

ABSTRACT

Osteoporosis and age-related bone loss are important public health concerns. Therefore, there is a high level of interest in the development of medical interventions and lifestyle changes that reduce the incidence of osteoporosis and age-related bone loss. Decreased bone mineral density is associated with high cholesterol, and patients on statins have increased bone mineral densities, strongly implicating cholesterol as a negative regulator of bone homeostasis. In this study, using both molecular and pharmacological approaches, we have been able to demonstrate that the primary cholesterol metabolite, 27-hydroxycholesterol, through its actions on both estrogen receptors and liver X receptors, decreases osteoblast differentiation and enhances osteoclastogenesis, resulting in increased bone resorbtion in mice. Induction of the short heterodimer partner protein by estrogens in osteoblasts can attenuate the liver X receptor-mediated actions of 27-hydroxycholesterol in bone. These data establish a mechanistic link between cholesterol and bone quality, highlight an unexpected target of estrogens in osteoblasts, and define a signaling axis, the therapeutic exploitation of which is likely to yield novel antiosteoporotic drugs.


Subject(s)
Bone and Bones/metabolism , Cholesterol/metabolism , Homeostasis , Hydroxycholesterols/pharmacology , Orphan Nuclear Receptors/drug effects , Receptors, Estrogen/drug effects , Animals , Bone Resorption/chemically induced , Cell Differentiation/drug effects , Liver X Receptors , Mice , Orphan Nuclear Receptors/metabolism , Osteoblasts/cytology , Osteoblasts/drug effects , Receptors, Estrogen/metabolism , Receptors, Steroid , Sterols
2.
Endocrinology ; 151(8): 3675-85, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20501668

ABSTRACT

Osteoporosis is an important clinical problem, affecting more than 50% of people over age 50 yr. Estrogen signaling is critical for maintaining proper bone density, and the identification of an endogenous selective estrogen receptor (ER) modulator, 27-hydroxycholesterol (27HC), suggests a mechanism by which nutritional/metabolic status can influence bone biology. With its levels directly correlated with cholesterol, a new possibility emerges wherein 27HC links estrogen and cholesterol signaling to bone homeostasis. In these studies, we found that increasing concentrations of 27HC, both by genetic and pharmacological means, led to decreased bone mineral density that was associated with decreased bone formation and increased bone resorption. Upon manipulation of endogenous estrogen levels, many of the responses to elevated 27HC were altered in such a way as to implicate ER as a likely mediator. In a model of postmenopausal bone loss, some pathologies associated with elevated 27HC were exacerbated by the absence of endogenous estrogens, suggesting that 27HC may act both in concert with and independently from classic ER signaling. These data provide evidence for interactions between estrogen signaling, cholesterol and metabolic disease, and osteoporosis. Patients with high cholesterol likely also have higher than average 27HC, perhaps putting them at a higher risk for bone loss and fracture. More studies are warranted to fully elucidate the mechanism of action of 27HC in bone and to identify ways to modulate this pathway therapeutically.


Subject(s)
Bone and Bones/drug effects , Homeostasis/drug effects , Hydroxycholesterols/pharmacology , Selective Estrogen Receptor Modulators/pharmacology , Animals , Bone Density/drug effects , Bone Resorption/chemically induced , Bone Resorption/genetics , Bone Resorption/metabolism , Bone and Bones/metabolism , Bone and Bones/physiology , Cholestanetriol 26-Monooxygenase/genetics , Cholestanetriol 26-Monooxygenase/metabolism , Cytochrome P450 Family 7 , Estradiol/pharmacology , Female , Homeostasis/genetics , Hydroxycholesterols/metabolism , Mice , Mice, Knockout , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteoblasts/physiology , Osteogenesis/drug effects , Osteogenesis/genetics , Osteogenesis/physiology , Selective Estrogen Receptor Modulators/metabolism , Steroid Hydroxylases/genetics , Steroid Hydroxylases/metabolism
3.
Mol Endocrinol ; 24(1): 33-46, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19901195

ABSTRACT

Selective estrogen receptor modulators (SERMs), such as tamoxifen (TAM), have been used extensively for the treatment and prevention of breast cancer and other pathologies associated with aberrant estrogen receptor (ER) signaling. These compounds exhibit cell-selective agonist/antagonist activities as a consequence of their ability to induce different conformational changes in ER, thereby enabling it to recruit functionally distinct transcriptional coregulators. However, the observation that SERMs can also regulate aspects of calcium signaling and apoptosis in an ER-independent manner in some systems suggests that some of the activity of drugs within this class may also arise as a consequence of their ability to interact with targets other than ER. In this study, we demonstrate that 4-hydroxy-TAM (4OHT), an active metabolite of TAM, directly binds to and modulates the transcriptional activity of the aryl hydrocarbon receptor (AHR). Of specific interest was the observation, that in the absence of ER, 4OHT can induce the expression of AHR target genes involved in estradiol metabolism, cellular proliferation, and metastasis in cellular models of breast cancer. The potential role for AHR in SERM pharmacology was further underscored by the ability of 4OHT to suppress osteoclast differentiation in vitro in part through AHR. Cumulatively, these findings provide evidence that it is necessary to reevaluate the relative roles of ER and AHR in manifesting the pharmacological actions and therapeutic efficacy of TAM and other SERMs.


Subject(s)
Receptors, Aryl Hydrocarbon/physiology , Receptors, Estrogen/physiology , Selective Estrogen Receptor Modulators/pharmacology , Tamoxifen/analogs & derivatives , Animals , Aryl Hydrocarbon Receptor Nuclear Translocator/genetics , Aryl Hydrocarbon Receptor Nuclear Translocator/metabolism , Breast Neoplasms/metabolism , Cell Differentiation/drug effects , Cell Line , Cell Line, Tumor , Chromatin Immunoprecipitation , Dose-Response Relationship, Drug , Female , Gene Expression Profiling , Gene Expression Regulation , Humans , Male , Mice , Osteoclasts/metabolism , Osteoclasts/physiology , Receptors, Aryl Hydrocarbon/genetics , Receptors, Aryl Hydrocarbon/metabolism , Receptors, Estrogen/deficiency , Receptors, Estrogen/genetics , Receptors, Estrogen/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Selective Estrogen Receptor Modulators/metabolism , Tamoxifen/metabolism , Tamoxifen/pharmacology
4.
Biol Reprod ; 80(2): 375-83, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18923163

ABSTRACT

Prunella vulgaris (PV), a commonly used Chinese herb, also known as Self-heal, has a wide range of reported medicinal activities. By screening multiple herbs using the endometrial cancer cell line, ECC-1, and an alkaline phosphatase detection assay, we found that PV displayed significant antiestrogenic activity. We investigated the possible usefulness of antiestrogenic activity using both in vitro and in vivo models of endometrial function. Using the well-differentiated, hormone-responsive endometrial cell line, ECC-1, PV extract, at concentrations that were not toxic to the cells, significantly reduced alkaline phosphatase activity and cell proliferation in response to estrogen in a dose-dependent manner. The expression of CYR61, an estrogen-induced protein, was blocked in ECC-1 cells by both the antiestrogen ICI 182,780 and PV extract. Interestingly, PV extract did not appear to directly inhibit estrogen signaling. Rather, we found that its activities were probably related to an ability to function as an aryl hydrocarbon receptor (AHR) agonist in ECC-1 cells. In support of this hypothesis, we noted that PV induced CYP1A1, CYP1B1, and AHR repressor expression in a dose-dependent manner--responses that were blocked by small interfering RNA treatment to reduce AHR and specific AHR antagonists. Ovariectomized immunodeficient RAG-2/gamma(c) knockout mice implanted with human endometrial xenografts developed implants only when treated with estrogen. Mice treated with estrogen and PV tea in their drinking water had fewer and smaller xenograft implants compared with their estrogen-treated counterparts that drank only water (P < 0.05). Analysis of the resulting implants by immunohistochemistry demonstrated persistent estrogen receptor (ER), but reduced proliferation and CYR61 expression. Mouse uterine tissue weight in PV-treated mice was not different from controls, and cycle fecundity of intact C57 female mice was unaffected by PV tea treatment. PV, or Self-heal, exhibits significant antiestrogenic properties, both in vitro and in vivo. This activity is likely due to the ability of PV-activated AHR to interfere with estrogen. This herb may be useful as an adjunct for the treatment of estrogen-dependent processes like endometriosis and breast and uterine cancers. Full characterization of this herb will likely provide new insights into the crosstalk between AHR and ESR1, with potential for therapeutic applications in women.


Subject(s)
Drugs, Chinese Herbal/pharmacology , Estrogen Receptor Modulators/pharmacology , Prunella , Animals , Cell Proliferation/drug effects , Drugs, Chinese Herbal/therapeutic use , Endometrial Neoplasms/drug therapy , Endometrial Neoplasms/genetics , Endometrial Neoplasms/metabolism , Endometrial Neoplasms/pathology , Estrogen Receptor Modulators/therapeutic use , Female , Humans , Mice , Mice, Inbred C57BL , Mice, Knockout , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Protein Binding , Prunella/chemistry , Receptors, Aryl Hydrocarbon/agonists , Receptors, Aryl Hydrocarbon/genetics , Receptors, Aryl Hydrocarbon/metabolism , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
5.
Trends Pharmacol Sci ; 29(10): 510-4, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18722677

ABSTRACT

The selective estrogen receptor modulators (SERMs) are synthetic pharmaceuticals, the relative agonist and antagonist activities of which are not equivalent in all cells. Their discovery has raised the possibility that endogenous small molecules might exist that have similar properties and could have important physiological roles. In support of this hypothesis is the recent demonstration that the oxysterol 27-hydroxycholesterol (27HC) interacts with and modulates the transcriptional activity of both estrogen receptor (ER) subtypes and that the relative agonist and antagonist activity of 27HC is influenced by both cell and promoter context. Although there is limited information available on the role of 27HC in classical estrogen-responsive tissues, that which is available in animal models of cardiovascular disease and cellular models of breast cancer support a role for this ligand in ER signaling. These results provide an interesting potential link between cholesterol (and cholesterol metabolism) and ER function, the physiological and pathological importance of which remains to be determined.


Subject(s)
Hydroxycholesterols/metabolism , Receptors, Estrogen/metabolism , Signal Transduction , Animals , Breast Neoplasms/physiopathology , Cardiovascular Diseases/physiopathology , Cholesterol/metabolism , Disease Models, Animal , Humans , Selective Estrogen Receptor Modulators/metabolism , Transcription, Genetic/physiology
6.
Mol Endocrinol ; 22(1): 65-77, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17872378

ABSTRACT

Selective estrogen receptor (ER) modulators (SERMs) are ER ligands whose relative agonist/antagonist activities vary in a cell- and promoter-dependent manner. The molecular basis underlying this selectivity can be attributed to the ability of these ligands to induce distinct alterations in ER structure leading to differential recruitment of coactivators and corepressors. Whether SERM activity is restricted to synthetic ligands or whether molecules exist in vivo that function in an analogous manner remains unresolved. However, the recent observation that oxysterols bind ER and antagonize the actions of 17beta-estradiol (E2) on the vascular wall suggests that this class of ligands may possess SERM activity. We demonstrate here that 27-hydroxycholesterol (27HC), the most prevalent oxysterol in circulation, functions as a SERM, the efficacy of which varies when assessed on different endpoints. Importantly, 27HC positively regulates both gene transcription and cell proliferation in cellular models of breast cancer. Using combinatorial peptide phage display, we have determined that 27HC induces a unique conformational change in both ERalpha and ERbeta, distinguishing it from E2 and other SERMs. Thus, as with other ER ligands, it appears that the unique pharmacological activity of 27HC relates to its ability to impact ER structure and modulate cofactor recruitment. Cumulatively, these data indicate that 27HC is an endogenous SERM with partial agonist activity in breast cancer cells and suggest that it may influence the pathology of breast cancer. Moreover, given the product-precursor relationship between 27HC and cholesterol, our findings have implications with respect to breast cancer risk in obese/hypercholesteremic individuals.


Subject(s)
Hydroxycholesterols/pharmacology , Receptors, Estrogen/agonists , Selective Estrogen Receptor Modulators/pharmacology , Amino Acid Sequence , Blotting, Western , Cell Line, Tumor , Cell Proliferation/drug effects , Chromatin Immunoprecipitation , Dose-Response Relationship, Drug , Estrone/chemistry , Estrone/pharmacology , HeLa Cells , Humans , Hydroxycholesterols/chemistry , Molecular Sequence Data , Molecular Structure , Promoter Regions, Genetic/genetics , Receptors, Estrogen/genetics , Receptors, Estrogen/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Selective Estrogen Receptor Modulators/chemistry , Selective Estrogen Receptor Modulators/metabolism , Sequence Homology, Amino Acid , Transcription, Genetic/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...